*EPA Honors 2012 Presidential Green Chemistry Challenge Award Winners*

WASHINGTON June 18, 2012: Today the U.S. Environmental Protection Agency recognized innovative chemical technologies that have the potential to prevent pollution in the United States. These awards recognize leading researchers and industrial innovators who create safer and more sustainable chemical designs, processes, and products that reduce the need to use chemicals that pollute the environment and threaten Americans' health. The awardees were honored during the 17th Annual Green Chemistry Challenge Awards Ceremony in Washington, D.C.

"EPA congratulates the 2012 winners for designing, developing, and implementing these innovative green chemistry technologies that will help create more sustainable industries and greener, safer products to protect people's health and the environment," said Jim Jones, EPA's acting assistant administrator for the Office of Chemical Safety and Pollution Prevention. "These are exciting technologies that have great potential to improve the safety of the detergents and personal care products we use in our homes; reduce energy consumption and hazardous waste in industrial metal production processes; improve the paper goods and plastics we use daily so that they are made with a smaller environmental footprint and can be recycled more effectively; and even a potential alternative to BPA-based can linings,"

The Presidential Green Chemistry Challenge Awards include five categories: Academic, Small Business, Greener Synthetic Pathways, Greener Reaction Conditions and Designing Greener Chemicals.

This year, EPA is recognizing two winning academic technologies: Robert M. Weymouth, PhD, Stanford University, Stanford, Calif., and James L. Hedrick, PhD, San Jose, Calif., for organic catalysis -- an innovation that removes hazardous metals used in the production of plastics. The technique creates a safer end product that allows bottle-to-bottle recycling, thereby providing an opportunity to reduce the millions of pounds of plastics that end up in landfills.

Geoffrey W. Coates, PhD, Cornell University, Ithaca, N.Y., for synthesizing biodegradable polymers from carbon dioxide and carbon monoxide that can be used in a wide range of adhesives, foams, plastic and potentially lead to the development of a BPA-alternative for use in can linings.

In the small-business category, Elevance Renewable Sciences, Inc., Woodridge, Ill., is being recognized for the production of high-performing, green specialty chemicals at advantageous costs. These green chemicals can be produced with less energy, significantly reduced greenhouse gas emissions compared to petrochemical technologies, and used in a wide range of consumer and industrial products and processes.

Winners in the "Greener Reaction Conditions, Designing Greener Chemicals, and Greener Synthetic Pathways," categories include:

Cytec Industries Inc., Woodland Park, N.J. for MAX HT "Bayer Process" scale inhibitor products that result in a drastically more energy efficient and less hazardous process for the production of alumina, a raw material for making aluminum. Application of this technology can result in reducing hazardous acid waste by millions of pounds annually and preventing billions of pounds of CO2 from being released into the atmosphere.

Buckman International, Inc., Memphis, Tenn., for enzymes to be used in papermaking that modify the cellulose in wood to increase the number of "fibrils" that bind the wood fibers to each other. The innovation produces paper with improved strength and quality without additional chemicals or energy. The process also allows papermaking with less wood fiber and higher percentages of recycled paper, enabling a single plant to save $1 million per year.

Go here to see the original:
EPA Honors 2012 Presidential Green Chemistry Challenge Award Winners

PRINCETON, N.J., June 18, 2012 /PRNewswire/ -- Covance Inc. (CVD) today announced that Steve Street, Ph.D., has joined the company as Global Vice President and General Manager, overseeing Covance's worldwide safety assessment and pharmaceutical chemistry services. He will be based in Harrogate, UK.

Dr. Street, with more than 27 years of experience in biopharmaceutical R&D, joins Covance from Pfizer, Inc., where he served as Vice President and Head of two global R&D units the Research Centers of Emphasis and Continuous Improvement. In these roles, he led the company's high-performing technology and operations group to increased portfolio development speed and project survival, ultimately creating a positive impact across multiple therapeutic areas, including chemistry and biology outsourcing, innovation, and new indications. During his tenure at Pfizer, Dr. Street also served as Head of the company's Worldwide Chemistry Discipline.

"Steve's keen strategic insights and exceptional R&D background will benefit Covance as we refine our global presence and strengthen our scientific expertise in early development," said Deborah Tanner, Executive Vice President and Group President, R&D Laboratories, Covance. "Science is at the core of everything we do, and the addition of a leader like Steve allows us to continue to meet clients' needs in this increasingly complex industry and, ultimately, remain the drug development partner of choice."

"Covance is known for its continuous global innovation in development, superior quality of products and services, and long-standing client relationships, all of which are essential elements for sustained success in today's highly competitive R&D landscape," said Dr. Street. "With an increasing focus on outsourcing, this is a very exciting time to transition from pharma to a contract research organization, and I am proud to join the industry leader. I look forward to learning from and working with a talented, dedicated group of new colleagues at Covance."

Dr. Street is a Fellow of the Royal Society of Chemistry, a member of the American Chemical Society, and recently served as a visiting Professor of Chemistry at the University of Nottingham, UK. He received a doctorate from Leeds University in the UK.

Covance generates more new drug development data than any other organization in the world. The company offers the industry's broadest and most integrated portfolio of R&D services, offering flexible, milestone-based solutions and full development solutions in clinical pharmacology, early clinical development, and molecule development.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

Forward Looking Statements

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

The rest is here:
Covance Appoints Dr. Steve Street to Lead Worldwide Safety Assessment and Pharmaceutical Chemistry Services

People News

Jun 18, 2012, 22:01 GMT

Andrew Garfield and Emma Stone

Emma Stone and Andrew Garfield had 'instant chemistry'.

The couple began dating after meeting on the set of 'The Amazing Spider-Man' and the actress loved working closely with the actor on the superhero movie and hoped their close bond is reflected in their characters.

Emma - who plays Gwen Stacy - said: 'It was really great to work with Andrew. We just had instant chemistry as soon as we were on set and I think it was great to be able to build that relationship.'

Emma has previously worked with hunky actors including Penn Badgley in 'Easy A' and Ryan Gosling in 'Crazy, Stupid, Love' and jokingly claimed she only agrees to appear in films with 'hot' co-stars.

Speaking at the UK premiere of 'The Amazing Spider-Man' in London's Leicester Square this evening (18.06.12), she told BANG Showbiz: 'I only seem to work with hot men and it''s pretty great to get that contractually written.'

The 23-year-old beauty also admitted she much prefers the 'romance' element to 'The Amazing Spider-Man' as she was more comfortable shooting those scenes than getting to grips with anything physical.

She said: 'The romance is my favourite part of filming because I don't do the action quite as well.'

Original post:
Emma Stone had instant chemistry with Andrew Garfield

Public release date: 18-Jun-2012 [ | E-mail | Share ]

Contact: Joan Coyle J_coyle@acs.org 202-872-6229 American Chemical Society

WASHINGTON, June 18, 2012 News media and others interested in advancing the role of green chemistry can join a panel discussion on Wednesday, June 20, during the 16th annual Green Chemistry & Engineering Conference. From 9:30 to 11:45 a.m. (EDT) the American Chemical Society Green Chemistry Institute (ACS GCI) will provide live streaming video of "Advancing Global Green Chemistry The Role of Government, Business and Academia." To participate, click here.

This free event will allow ACS GCI to utilize state-of-the-art technology to further enhance the profile and importance of green chemistry while linking the global green chemistry community. All green chemistry enthusiasts, including chemists, engineers, researchers, policy analysts, managers/directors, venture capitalists, chemistry and engineering students, chemistry and business school professors and others are encouraged to participate.

Panelists Include:

Each panelist will provide a 15-minute presentation followed by a 10-minute question-and-answer session. Virtual audience members will submit questions for the panelists via a secure web server, and a moderator will assist the panelists with the flow of questions and responses.

###

Please click here to register. Advance registration enables attendees to submit questions before the session and to receive a reminder email and password the day before the session.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

The ACS Green Chemistry Institute is an organization focused on catalyzing and enabling the implementation of green chemistry and engineering throughout the global chemical enterprise. ACS GCI operates industrial roundtables; conducts conferences, seminars and training; maintains an international network of 26 green chemistry chapters; and with its partner NSF International, led the effort to establish the first consensus standard for greener chemical products and process information in the United States.

Continued here:
Advancing Global Green Chemistry -- The role of government, business and academia

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON , June 18, 2012 /CNW/ - Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

In their linear form, however, peptides are unstable. When used as drug-delivery agents, they break down before reaching therapeutic targets or fail to permeate cell walls, presenting a long-standing challenge to medicinal chemists.

Encycle's breakthrough chemistry platform stabilizes linear peptides for drug development by cyclizing them. This process has demonstrably increased the drug-like properties of these molecules, increasing their stability in the body and providing a higher degree of cell permeability. The platform adapts to any linear peptide input and has the power to generate libraries of compounds to facilitate drug discovery and development.

This technology, discovered in Professor Andrei Yudin 's chemistry laboratory at the University of Toronto , will be developed with the collaboration of Professor Eric Marsault, specialized in medicinal chemistry at the Institut de Pharmacologie de Sherbrooke of Universit de Sherbrooke. Together, they will demonstrate that Encycle's foundational chemistry technology functions for a wide variety of peptides and that the platform can hit therapeutic targets of interest. Encycle will then be well positioned to pursue discovery-stage relationships with the pharmaceutical partners involved in the project around targets of their choosing.

"It costs over $1 billion to bring a new drug to market under the current high through-put pharmaceutical discovery model," says Yudin, professor of Chemistry at U of T and Encycle Founder. "Instead of randomly searching millions of compounds, Encycle's platform will allow us to design a peptide molecule with small molecule properties, such as stability and cell permeability, while remaining more likely to interact with a targeted therapeutic area. In theory, this approach would save time, money and reduce overhead risk."

"The approach pioneered by Andrei Yudin is remarkable for its efficiency in the synthesis of macrocycles, which are otherwise very difficult to reach and thus difficult to exploit in drug discovery," says Marsault. "This collaboration will unlock the potential of this class and provide much-needed new classes of drug candidates able to mimic the natural structural elements of proteins."

"This innovative project is a successful result of our established commitment towards technology transfer of excellent research and partnering with the private and public sectors," says Jacques Beauvais , vice-rector of research at the Universit de Sherbrooke.

The project has received $1 million in seed funding, largely derived through The Qubec Consortium for Drug Discovery's funding programs, and has attracted interest from four pharmaceutical companies.

Read more here:
Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Cytec Wins EPA Presidential Green Chemistry Award

Woodland Park, New Jersey, June 18, 2012 - Today, Cytec Industries Inc. (CYT) was awarded the top honor in green chemistry, the Presidential Green Chemistry Challenge Award. The award, created by the Environmental Protection Agency (EPA), recognizes companies that have pioneered sustainable technologies that incorporate the principles of green chemistry. Cytec`s MAX HT scale control technology enables greener conditions within the Bayer process, a process used for converting bauxite ore to alumina, the primary raw material for aluminum. The innovation reduces pollution at the source in addition to reducing energy use and waste generation. "Cytec has been a pioneer in developing innovative solutions for the mining industry while maintaining a focus on sustainable technologies. We are honored to receive such a prestigious award from the EPA," said Shane Fleming, Cytec`s Chairman, President, and CEO.

Today`s green chemistry award recognizes one of the many technology innovations Cytec has achieved within its In Process Separation business segment. MAX HT Bayer Sodalite Scale Inhibitor is the first scale inhibitor product in the market for this application and solves a legacy production challenge within the alumina industry. This technology provides benefits by reducing or eliminating the scale formation in heat exchangers resulting in higher heat transfer rates while reducing energy consumption and waste generation. "The realized energy saving for the combined customers currently utilizing our MAX HT technology is approximately 47 trillion Btu, which is the equivalent of up to 8 billion pounds of carbon dioxide (CO2) not released to the atmosphere," said Martin Court, Cytec`s Vice President, In Process Separation business. Martin added, "Fewer cleaning cycles also result in a realized annual hazardous waste reduction of up to 200 million pounds in total for all of the current operations using this product."

Cytec`s sustainability strategy is focused on developing innovative and environmentally sustainable products that compete in a global economy; achieving the highest standards of safety, health and environmental stewardship and operational excellence. The company uses business-specific market drivers and best practices to drive the sustainability efforts.

Corporate Profile Cytec`s vision is to deliver specialty chemical and material technologies beyond our customers` imagination. Our focus on innovation, advanced technology and application expertise enables us to develop, manufacture and sell products that change the way our customers do business. Our pioneering products perform specific and important functions for our customers, enabling them to offer innovative solutions to the industries that they serve. Our products serve a diverse range of end markets including aerospace composites, structural adhesives, automotive and industrial coatings, electronics, inks, mining and plastics.

Contact: Jodi Allen Communications and Investor Relations (973) 357-3283

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Cytec Industries Inc via Thomson Reuters ONE HUG#1620380

Read this article:
Cytec Wins EPA Presidential Green Chemistry Award